^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Baituowei (goserelin acetate sustained-release microspheres for injection)

    i
    Other names: LY01005, LY 01005, LY-01005
    Associations

    News

    Trials
    Company:
    BeiGene, Luye Group
    Drug class:
    GnRH stimulant
    Related drugs:
    Associations

    News

    Trials
    7ms
    To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial
    |
    goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)
    over1year
    Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial. (PubMed, Chin Med J (Engl))
    LY01005 is as effective as goserelin implants in reducing testosterone to castration levels, with a similar safety profile.
    P3 data • Journal • Head-to-Head
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    over1year
    Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P1, N=23, Completed, Luye Pharma Group Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Baituowei (goserelin acetate sustained-release microspheres for injection)
    over1year
    Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P3, N=188, Completed, Luye Pharma Group Ltd. | Recruiting --> Completed
    Trial completion
    |
    ER (Estrogen receptor)
    |
    tamoxifen • goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)
    3years
    Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX® (clinicaltrials.gov)
    P3; N=188; Recruiting; Sponsor:Luye Pharma Group Ltd.
    New P3 trial • Clinical
    |
    ER (Estrogen receptor)
    |
    goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)